0.87
4.65%
-0.0424
Amarin Corp ADR 주식(AMRN)의 최신 뉴스
Amarin Corp ADR [AMRN] President and CEO makes an insider purchase of 14426 shares worth 15724.0. – Knox Daily - Knox Daily
Knox Daily
Amarin Corp ADR (AMRN) expanding its growth trajectory ahead – Sete News - SETE News
SETE News
Amarin Corp ADR [AMRN] Investment Guide: What You Need to Know – Knox Daily - Knox Daily
Knox Daily
Amarin Corp ADR (AMRN) stock on the rise: An overview – US Post News - US Post News
US Post News
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
GlobeNewswire Inc.
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Zacks Investment Research
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
Zacks Investment Research
Does Amarin Corp ADR (AMRN) offer a good opportunity for investors? – Sete News - SETE News
SETE News
Amarin's (AMRN) Q1 Earnings and Revenues Surpass Estimates
Zacks Investment Research
Amarin Plc (AMRN) Q1 2024 Earnings Call Transcript
The Motley Fool
Exelixis (EXEL) Q1 Earnings Miss, Cabometyx Sales Fall Short
Zacks Investment Research
A year in review: Amarin Corp ADR (AMRN)'s performance in the last year – US Post News - US Post News
US Post News
A year in review: Amarin Corp ADR (AMRN)'s performance in the last year – US Post News - US Post News
US Post News
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
GlobeNewswire Inc.
Amarin Announces Results of Annual General Meeting of Shareholders
GlobeNewswire Inc.
Amarin Corp ADR's latest rating changes from various analysts – Knox Daily - Knox Daily
Knox Daily
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
GlobeNewswire Inc.
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
GlobeNewswire Inc.
Amarin (AMRN) Up 7% on Intellectual Property Wins in Europe
Zacks Investment Research
Why Amarin Stock Was Rocketing Higher on Wednesday
The Motley Fool
Why Amarin Stock Was Rocketing Higher on Wednesday - sharewise
sharewise
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo
GlobeNewswire Inc.
Amarin's (AMRN) Q4 Earnings and Revenues Surpass Estimates
Zacks Investment Research
Amarin Plc (AMRN) Q4 2023 Earnings Call Transcript
The Motley Fool
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Can Rising Operating Costs Affect Acadia's (ACHC) Q4 Earnings?
Zacks Investment Research
Can Higher Admissions Drive Universal Health (UHS) Q4 Earnings?
Zacks Investment Research
Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect
Zacks Investment Research
Can Low Occupancy Rate Affect Select Medical (SEM) Q4 Earnings?
Zacks Investment Research
Altimmune (ALT) to Report Q4 Earnings: What's in the Cards?
Zacks Investment Research
Amarin to Report Fourth Quarter and Full Year 2023 Financial Results and Host Conference on February 29, 2024
GlobeNewswire Inc.
5 Biotech Stocks Likely to Outpace Q4 Earnings Estimates
Zacks Investment Research
Amarin Chairman & CEO Issue Letter to Shareholders
GlobeNewswire Inc.
Are Medical Stocks Lagging Amarin (AMRN) This Year?
Zacks Investment Research
Why TechTarget Shares Are Trading Higher By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Aspen Aerogels Issues Business Update, Joins Plug Power, SunPower And Other Big Stocks Moving Lower On Thursday
Benzinga
Why Amarin Stock Skyrocketed Today
The Motley Fool
Crude Oil Falls 1%; Amarin Shares Spike Higher
Benzinga
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Nasdaq Gains 50 Points; US Crude Inventories Rise Last Week
Benzinga
Amarin Provides Preliminary Fourth Quarter 2023 Selected Financials and Outlines Key Priorities For 2024
GlobeNewswire Inc.
Why Is Amicus Therapeutics (FOLD) Up 15% Since Last Earnings Report?
Zacks Investment Research
What Makes Amarin (AMRN) a New Buy Stock
Zacks Investment Research
3 Biotech Stocks to Avoid Like the Plague - InvestorPlace
InvestorPlace
Amarin Fish-Oil Heart Drug Good News Is Already Priced In Stock - Bloomberg
Bloomberg
Amarin Fish Oil Capsule Vascepa Gets ICER Value Stamp - Bloomberg
Bloomberg
Amarin (AMRN) Surges on Booming Heart Pill Sales - Bloomberg
Bloomberg
Amarin (AMRN) Fish-Oil Heart Medicine Win Is Rarest Drug Success - Bloomberg
Bloomberg
자본화:
|
볼륨(24시간):